Related Experiment Videos

[Community-acquired pneumonia: serum adenosine-deaminase activity in the aetiological diagnosis]

Ramón Fernández Alvarez1, Luis Molinos Martín, José Antonio Gullón Blanco

  • 1Sección de Neumología, Hospital Universitario de Canarias, La Laguna, Tenerife, España. ENELLANO@terra.es

Medicina Clinica
|October 31, 2002
PubMed
Abstract

Insights

Plasmatic adenosine deaminase (ADAp) levels are elevated in community-acquired pneumonia (CAP) patients with atypical pathogens. Factors like liver disease and diabetes also increase ADAp, suggesting its use as an etiologic marker for CAP.

Area of Science:

  • Biochemistry
  • Immunology
  • Infectious Diseases

Context:

  • Adenosine deaminase (ADA) is an enzyme linked to immune system activity.
  • Elevated serum ADA levels have been observed in community-acquired pneumonia (CAP), particularly with atypical microorganisms.
  • Previous research indicates ADA increases in non-infectious conditions, necessitating further investigation into influencing factors.

Purpose:

  • To investigate factors influencing plasmatic ADA (ADAp) levels in CAP patients.
  • To determine the association between ADAp levels and specific etiologies, comorbidities, and complications in CAP.
  • To evaluate ADAp as a potential diagnostic marker for CAP.

Summary:

  • A study analyzed 245 CAP cases and 49 controls, examining ADAp activity in relation to causative organisms, comorbidities, and complications.
  • Results showed significantly increased ADAp levels in CAP cases attributed to atypical microorganisms.
  • Independent predictors for elevated ADAp included atypical etiology (OR=5.9), liver disease (OR=5.8), diabetes mellitus (OR=1.9), and prior antibiotic use (OR=1.7).

Impact:

  • Plasmatic ADAp can serve as an etiologic marker, aiding in the empiric treatment approach for CAP.
  • Understanding factors influencing ADAp levels can improve diagnostic accuracy and patient management strategies for pneumonia.
  • This research highlights the potential of ADAp as a biomarker in differentiating CAP causes and guiding clinical decisions.

Related Concept Videos